

# Decisions of the Annual General Meeting of Biohit Oyj

Biohit Oyj Decisions of the Annual General Meeting, June 15, 2022 at 4.00 pm local time (EET)

The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday June 15, 2022 approved the financial statements for the financial year 2021 based on a vote. Based on a vote the AGM decided to discharge the members of the Board of Directors and the President and CEO from liability for the financial year 2021. Based on a vote the AGM decided to approve the Remuneration Report of the company's Governing Bodies presented to the AGM; the decision is advisory.

## **Distribution of dividends**

With a unanimous decision of the shareholders participating in the AGM the AGM resolved in accordance with the proposal of the Board of Directors that no dividend is paid for the financial period ended on December 31, 2021.

## **Members of the Board of Directors**

Based on a vote the AGM resolved that five (5) members are elected to the Board of Directors and that professor Osmo Suovaniemi, CEO Franco Aiolfi, Ph.D. Lea Paloheimo, CEO Liu Feng and CEO Kalle Härkönen are elected as members of the Board of Directors until the end of the next AGM.

Additionally, the AGM resolved based on a vote that the Chairman of the Board of Directors and the other members of the Board of Directors are paid a meeting fee of EUR 1,500.

## **Election of the Auditor and remuneration for the Auditor**

With a unanimous decision of the shareholders participating in the AGM the AGM elected authorized public accountants PricewaterhouseCoopers Oy as the company's auditor until the end of the next AGM and that the auditor is paid remuneration according to invoice approved by the company.

## **Authorisation of the Board of Directors to decide on the issue of shares and to issue special rights entitling to shares**

Based on a vote the AGM authorised the Board to decide on the issue of shares and to issue special rights referred to in Chapter 10, Section 1 of the Limited Liability Companies Act entitling to shares with the following terms and conditions:

The maximum number of new Series B shares to be issued pursuant to the authorisation is 2 000 000, which corresponds to approximately 16.6 % of the company's all existing Series B shares.

The authorisation includes the Board of Directors' entitlement to decide on all terms and conditions regarding the share issue and the issue of special rights. The share issue and the issue of special rights entitling to shares can occur in derogation from the pre-emptive subscription

right of the shareholders (directed issue).

The authorisation remains valid for two (2) years from the resolution of the Annual General Meeting. This authorisation replaces the authorisation given by the Annual General Meeting held on 16 September 2020, but it does not replace the authorisation given by the Extraordinary General Meeting held on 9 March 2022.

The minutes of the AGM will be available for review by shareholders by Monday June 20, 2022 on the company's website ([www.biohithealthcare.com/investors](http://www.biohithealthcare.com/investors)) and at the corporate headquarters of Biohit Oyj, located at Laippatie 1, 00880 Helsinki.

**Additional information:**

CEO Päivi Siltala, Biohit Oyj  
tel. +358 9 773 861

[investor.relations@biohit.fi](mailto:investor.relations@biohit.fi)  
[www.biohithealthcare.com](http://www.biohithealthcare.com)

*Biohit in brief*

*Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. [www.biohithealthcare.com](http://www.biohithealthcare.com)*